BMO Capital lowered the firm’s price target on Regeneron (REGN) to $600 from $800 and keeps an Outperform rating on the shares. The firm is updating its model following “disappointing” results for itepekimab in COPD, noting that with only one of the two phase 3 studies reaching statistical significance and the path forward for approval more difficult, it is lowering its probability of success for itepekimab to 0%, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Sanofi price target lowered to EUR 108 from EUR 121 at Guggenheim
- Regeneron enters strategic licensing with Hansoh Pharmaceuticals
- Regeneron price target lowered to $755 from $958 at Morgan Stanley
- Regeneron’s announces results of Phase 2 trial of semaglutide+trevogrumab
- Optimistic Outlook on Regeneron Despite Mixed AERIFY Trial Results